Présentation de l'entreprise
DNA X, Inc., known under the ticker SONM, operates as a provider of enterprise 5G solutions across the United States, Canada, Europe, the Middle East, and the Asia Pacific region. The company focuses on the software infrastructure sector, specifically within the technology industry, where it supplies ruggedized cell phones designed for task workers, including models such as the Sonim XP10, XP5plus, XP3plus, XP Pro, XP100 4G, and XP400 5G. With a market capitalization of $4.91 million and an annual revenue of $59.11 million, the firm employs a workforce of 131 individuals. These valuation and revenue figures indicate that DNA X, Inc. is a micro-cap entity operating with a relatively modest scale compared to large-cap technology peers, reflecting a niche position in the specialized hardware market rather than broad consumer electronics dominance.
Santé financière
The company reported revenue of $59.11 million over the trailing twelve months, yet it posted a net income loss of $33,384,000 and an EBITDA of $-28,269,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses heavily outweigh gross profits, resulting in a loss of over $33 million before interest and taxes. Free cash flow stands at $-12,125,375, which signifies a lack of immediate financial flexibility and suggests the company is burning cash rather than generating liquidity from its core operations. Analyzing the three primary margins shows a gross margin of 17.9%, an operating margin of -24.5%, and a profit margin of -56.5%; these figures indicate that while the product has some pricing power, the high operational costs are eroding profitability at a severe rate. Regarding liquidity and leverage, the company holds $2.14 million in cash against $5.07 million in debt, and the debt-to-equity ratio is listed as N/A, implying a capital structure heavily weighted toward equity financing or a lack of traditional equity base due to losses. The current ratio of 0.78 indicates that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity pressures. Finally, the return on equity is -455.8% and the return on assets is -44.3%, metrics that reveal management is currently generating negative returns on both shareholders' capital and the total asset base.
Évaluation de la valorisation
The valuation metrics for DNA X, Inc. present a mixed picture with a P/E ratio (TTM) listed as N/A due to negative earnings, while the forward P/E stands at 3.93. The discrepancy between the unavailable trailing multiple and the low forward multiple implies that the market is pricing in a significant expected turnaround in earnings trajectory or is relying on future profitability rather than historical performance. The price-to-book ratio is -4.78, which indicates a negative book value and suggests the market is valuing the company well below its accounting equity, often a sign of distressed valuation or intangible-heavy business models. Alternative valuation metrics include a price-to-sales ratio of 0.08 and an EV/EBITDA of -0.22, which suggest the company is trading at a fraction of its sales revenue and possesses negative enterprise value relative to earnings. The stock trades within a wide range, having reached a 52-week high of $38.52 and a 52-week low of $2.52, meaning the current price sits significantly below the yearly peak but remains above the absolute floor of the trading range. The beta value of 1.72 indicates that the stock exhibits high price volatility, moving with greater intensity than the broader market and carrying higher systematic risk for investors seeking stability.
Growth & Income
DNA X, Inc. demonstrated revenue growth of 7.9% year-over-year, whereas earnings growth is N/A due to the reported net loss. Since the company is currently unprofitable, earnings cannot grow at a faster or slower rate than revenue in the traditional sense, but the expansion of sales while maintaining losses suggests a growth-at-any-cost strategy typical of early-stage or turnaround technology firms. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This approach implies that the firm reinvests its limited capital, primarily from cash reserves of $2.14 million, back into operations, research, or expansion efforts rather than paying dividends to investors. The overall growth and income profile is characterized by double-digit revenue expansion coupled with significant financial losses and no income distribution, presenting a high-risk, high-reward dynamic focused on long-term market capture rather than immediate shareholder returns.